Porcine peptide and amino-acid mixture
No FDA-approved product identified for this exact research entry in the targeted review.
The 2025 C-REGS 2 study reported better 90-day disability outcomes with added Cerebrolysin. It was an open-label comparative-effectiveness study, so the association does not have the causal strength of a blinded randomized trial.1
This blend contains multiple compounds and has no single amino-acid sequence.
Product-level trial findings do not identify one active peptide.
The 2025 C-REGS 2 study reported better 90-day disability outcomes with added Cerebrolysin. It was an open-label comparative-effectiveness study, so the association does not have the causal strength of a blinded randomized trial.1
Reference sequence: early effects/dizziness; neurological/cognitive change; motor recovery; plateau. Early-treatment windows, including 72 hours, are indication-specific; benefit unguaranteed.22
These are reported timelines, not a prediction of your response.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IVUndiluted IV slow push over 3 minutes | Up to 10 mL | Once daily | Small Volume IVReference report | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) | 22 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| IMUndiluted IM injection over 3 minutes | Up to 5 mL | Once daily | Intramuscular (Lower Doses)Reference report | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) | 22 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| IVIV infusion (diluted to 100mL minimum) | 20-50 mL | Once daily for 10-21 days | Acute StrokeReference report | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) | 22 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| IVIV infusion (diluted to 100mL minimum) | 20-50 mL | Once daily for 7-30 days | Traumatic Brain InjuryReference report | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) | 22 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| IVIV injection/infusion (2-4 cycles yearly) | 10-30 mL | 5 days weekly for 4 weeks | Alzheimer's DiseaseReference report | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) | 22 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| IVIV injection/infusion (2-4 cycles yearly) | 10-30 mL | 5 days weekly for 4 weeks | Vascular DementiaReference report | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) | 22 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
As soon as possible for acute conditions; morning preferred
The preparation is a mixture, so individual peptide identities and exposures are not interchangeable with isolated research peptides.
1The Cochrane assessment identified increased nonfatal serious adverse events in acute-stroke trials.
2Reference cites epilepsy and severe renal insufficiency.
Anaphylaxis/rash, seizure, cardiovascular events, worsening renal function, dizziness or agitation require assessment.
Mixed trial findings and research-integrity concerns prevent a blanket efficacy conclusion.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Additive neurological effects.22
Reference report · Pep-Pedia label: Monitor CombinationAdditive neurological effects.22
Reference report · Pep-Pedia label: Use CautionOverstimulation concern.22
Reference report · Pep-Pedia label: Monitor CombinationNo blanket safe-combination conclusion.22
Reference report · Pep-Pedia label: CompatiblePossible cognitive effects; not safety guarantee.22
Reference report · Pep-Pedia label: CompatibleInfusion compatibility issue.22
Reference report · Pep-Pedia label: Avoid CombinationSame-infusion warning, not universal co-use ban.22
Reference report · Evidence context: Do not mix claimSame-infusion warning.22
Reference report · Pep-Pedia label: Avoid CombinationNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.3
Research contextNo matching interactions. Try another name or filter.
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.3
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
The source describes ready-made ampoules for clinical IM or IV use.
Sodium chloride appears as a catheter-flush solution, not as evidence of a universal reconstitution solvent. The source describes clinical administration; follow the applicable product and facility instructions.
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Product-specific administration is required; this entry is not a single-mass peptide vial.2
Amounts are total blend mass. Formulas and ratios vary. Approved and research products are not interchangeable.
The available sources describe prepared products or do not establish a reconstitution method.22
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Randomized evidence, treatment setting and observational results must be interpreted separately.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Cerebrolysin is a prepared mixture of porcine-brain peptides and amino acids studied in neurological disorders. Findings differ by outcome and study design; favorable recovery studies do not establish a mortality benefit after acute stroke.
No FDA-approved product identified for this exact research entry in the targeted review.
Porcine brain-derived peptide and amino-acid preparation2
Neurotrophic/neuroprotective activity is proposed; mixture findings do not establish individual-peptide effects.22
The 2025 C-REGS 2 study reported better 90-day disability outcomes with added Cerebrolysin. It was an open-label comparative-effectiveness study, so the association does not have the causal strength of a blinded randomized trial.
1The 2023 Cochrane review found probably little or no mortality benefit and an increase in nonfatal serious adverse events in Cerebrolysin trials. Later observational findings do not resolve this randomized-evidence concern.
2Stroke rehabilitation research. The 2025 C-REGS 2 study reported better 90-day disability outcomes with added Cerebrolysin. It was an open-label comparative-effectiveness study, so the association does not have the causal strength of a blinded randomized trial.1
Cognition. Alzheimer disease, vascular dementia and post-stroke cognition.22
Neuroprotection. Acute stroke, traumatic brain injury and subarachnoid hemorrhage.22
Recovery. Motor function, neurological scores and independence; positive score changes do not ensure functional benefit.22
Pep-Pedia discusses neurological recovery research.3
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Added 2025 C-REGS 2 observational evidence and the 2023 Cochrane assessment; their designs and conclusions remain distinct.
AI-prepared summaries. Independent medical editorial review is pending.
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source displays “166 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
Original sources and review status. Open a reference to read its summary.
This prospective open-label comparative-effectiveness study reported better 90-day disability outcomes with Cerebrolysin plus standard care; its observational design remains susceptible to confounding.
The 2025 C-REGS 2 study reported better 90-day disability outcomes with added Cerebrolysin. It was an open-label comparative-effectiveness study, so the association does not have the causal strength of a blinded randomized trial.
Additional research · Checked 2026-10-12
A Cochrane review found probably little or no effect on all-cause death and identified increased nonfatal serious adverse events in Cerebrolysin trials; evidence was current to June 2022.
The 2023 Cochrane review found probably little or no mortality benefit and an increase in nonfatal serious adverse events in Cerebrolysin trials. Later observational findings do not resolve this randomized-evidence concern.
Additional research · Checked 2026-10-12
Secondary editorial profile and reported practices; not clinical validation.
Pep-Pedia reports: A review of ten studies totaling 8,749 TBI patients reportedly found improvements in GCS/GOS neurological scores.
Reported population / model
Humans
Reported study details
10-50 mL daily · Variable duration · GCS/GOS improvements
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The source describes improved neurological scales after moderate-to-severe TBI in a randomized study; detailed effect sizes are not supplied.
Reported population / model
Humans
Reported study details
30-50 mL daily · 10-28 days · Significant neurological improvement
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Favorable six-month outcomes were reported in 76% versus 48% in the pilot subarachnoid-hemorrhage trial.
Reported population / model
Humans
Reported study details
30 mL daily · 14 days · Improved 6-month outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: A nine-trial stroke analysis reportedly favored treatment on NIHSS, with a reported NNT of 7.7 across 1,879 patients.
Reported population / model
Humans
Reported study details
30-50 mL daily · 10-21 days · NIHSS improvement, NNT=7.7
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: A separate 1,779-patient stroke analysis found no significant improvement on modified Rankin or Barthel functional scales.
Reported population / model
Humans
Reported study details
Various doses · 72-hour window · No significant mRS/BI improvement
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Small cognitive changes were reported in Alzheimer's studies; whether these translate into meaningful daily-life improvement remains uncertain.
Reported population / model
Humans
Reported study details
30 mL daily · 4 weeks · Modest cognitive improvements
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: A nine-trial stroke analysis reportedly favored treatment on NIHSS, with a reported NNT of 7.7 across 1,879 patients.
Reported population / model
Humans
Reported study details
30-50 mL daily · 10-21 days · NIHSS improvement, NNT=7.7
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
Pep-Pedia reports: A separate 1,779-patient stroke analysis found no significant improvement on modified Rankin or Barthel functional scales.
Reported population / model
Humans
Reported study details
Various doses · 72-hour window · No significant mRS/BI improvement
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The source describes improved neurological scales after moderate-to-severe TBI in a randomized study; detailed effect sizes are not supplied.
Reported population / model
Humans
Reported study details
30-50 mL daily · 10-28 days · Significant neurological improvement
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: A review of ten studies totaling 8,749 TBI patients reportedly found improvements in GCS/GOS neurological scores.
Reported population / model
Humans
Reported study details
10-50 mL daily · Variable duration · GCS/GOS improvements
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Favorable six-month outcomes were reported in 76% versus 48% in the pilot subarachnoid-hemorrhage trial.
Reported population / model
Humans
Reported study details
30 mL daily · 14 days · Improved 6-month outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Small cognitive changes were reported in Alzheimer's studies; whether these translate into meaningful daily-life improvement remains uncertain.
Reported population / model
Humans
Reported study details
30 mL daily · 4 weeks · Modest cognitive improvements
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
Lists a half-life of 1 hr and a peak time of 30 min. Stated attribution: EVER Pharma data. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12